Select Page

For more than 20 years, the Clinique médicale l’Actuel, under the direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.

Innovative Strategies for the Management of HIV Infection

with Dr. Jean-Guy Baril and Dr. Réjean Thomas



  • Innovative treatments in HIV
  • Special populations and possible treatments for these populations
  • Ongoing studies

This activity is supported by
an educational grant from:




During this presentation, Dr. Jean-Guy Baril discusses innovative therapies in the treatment of HIV, especially in the case of special populations in which current treatments cannot be used.

Dr. Baril also presented a patient case and discussed some ongoing studies.

Réjean Thomas, MD, DHC

Réjean Thomas, MD, DHC


CEO | Founder
Clinique médicale l’Actuel:
Centre of Excellence HIV – STI – Hepatitis

Affiliated with the Centre hospitalier de l’Université de Montréal (CHUM)
Quebec, Canada

Jean-Guy Baril, MD

Jean-Guy Baril, MD


Clinique médicale Quartier latin
Centre hospitalier de l’Université de Montréal (CHUM)
Québec, Canada



Only Logged in users can see the full program

ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Réjean Thomas, MD has a financial interest/relationship or affiliation in the form of:
Advisory: AbbVie, Bristol-Myers Squibb Janssen, Gilead, Merck, ViiV Healthcare.

Jean-Guy Baril, MD has a financial interest/relationship or affiliation in the form of:
Consultant: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck Frosst , Pfizer, Roche, Tibotec.

Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.